Skip to main content
impaact logo Return to homepage
  • Contact
    • Directory
  • About
    • Mission
    • Network Structure
      • Leadership
    • Areas of Research
      • Cure & Immunotherapy
      • Brain & Mental Health
      • Therapeutics
      • Tuberculosis
      • Social Behavioral Scientific Core (SBSC)
    • Early Career Investigator Program
    • Staff Spotlights
    • Funding Acknowledgements
    • Network Sites
      • Study Site Map
  • Studies
    • Research and Study Opportunities
    • Submit a Research Proposal
    • IMPAACT Study Snapshots
  • Community Engagement
    • ICAB Leadership Group
    • IMPAACT Community Advisory Board (ICAB)
    • Operations Center Staff
    • Resources
      • Acronyms
    • Site Community Advisory Boards
    • Community Meetings and Webinars
  • News & Events
    • Events and Conferences
    • IMPAACT Annual Meeting
    • Newsletters
    • Past Conference Presentations
    • Spotlight Series
  • Resources
    • COVID-19 Resources
    • HIV/AIDS Network Coordination (HANC)
    • Lab Center
      • Laboratory Committees
      • Laboratory Guidance Documents
      • Laboratory Resources for Quality Management
      • MiLab Resources
      • Specimen Repository
    • Manual of Procedures
    • Media Release Form
    • Network Logos & Templates
    • Regulatory Resources
    • Training Opportunities
    • NIH Updates
  • Publications
    • Abstracts
    • Manuscripts
  • Enter a search term.
Back to Directory

Rochelle Rogers

Email

rochelle.rogers@nih.gov

Phone

240-651-6818

Institution

Pharmaceutical Affairs Branch, Division of AIDS

Address

Pharmaceutical Affairs Branch
Division of AIDS/OCSO/NIAID/NIH
5601 Fishers Lane
Rockville, MD 20852
USA
Request an Update

Affiliated Studies

IMPAACT 2049: LEAP

DAIDS Number

TBA

Research Area

Tuberculosis

Study Status

In Development

P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study

DAIDS Number

11954

Research Area

Cure and Immunotherapy

Study Status

Enrolling

IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1

DAIDS Number

38962

Research Area

Therapeutics

Study Status

Pending

IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1

DAIDS Number

38953

Research Area

Therapeutics

Study Status

Pending
IMPAACT logo Return to homepage

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.

Stay connected with the IMPAACT Network

Follow IMPAACT

Sign up for our newsletter

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Sitemap Privacy Notice

© 2020 IMPAACT Network